- Home
- KRON vs APLT Comparison
KRON vs APLT Comparison
Compare KRON & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- APLT
- Stock Information
- Founded
- KRON 2017
- APLT 2016
- Country
- KRON United States
- APLT United States
- Employees
- KRON N/A
- APLT N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- APLT Health Care
- Exchange
- KRON Nasdaq
- APLT Nasdaq
- Market Cap
- KRON 41.0M
- APLT 37.5M
- IPO Year
- KRON 2020
- APLT 2019
- Fundamental
- Price
- KRON $0.67
- APLT $0.36
- Analyst Decision
- KRON Buy
- APLT Buy
- Analyst Count
- KRON 3
- APLT 7
- Target Price
- KRON $1.63
- APLT $6.10
- AVG Volume (30 Days)
- KRON 826.3K
- APLT 2.7M
- Earning Date
- KRON 06-10-2025
- APLT 05-13-2025
- Dividend Yield
- KRON N/A
- APLT N/A
- EPS Growth
- KRON N/A
- APLT N/A
- EPS
- KRON N/A
- APLT N/A
- Revenue
- KRON $9,192,000.00
- APLT $265,000.00
- Revenue This Year
- KRON N/A
- APLT $1,768.13
- Revenue Next Year
- KRON N/A
- APLT $332.85
- P/E Ratio
- KRON N/A
- APLT N/A
- Revenue Growth
- KRON 21.16
- APLT N/A
- 52 Week Low
- KRON $0.65
- APLT $0.30
- 52 Week High
- KRON $1.60
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- KRON 33.35
- APLT 42.18
- Support Level
- KRON $0.66
- APLT $0.37
- Resistance Level
- KRON $0.75
- APLT $0.40
- Average True Range (ATR)
- KRON 0.03
- APLT 0.06
- MACD
- KRON 0.00
- APLT -0.01
- Stochastic Oscillator
- KRON 19.47
- APLT 3.72
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.